CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-2.22%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$5.91M
(+0.55%)
Cap. Flow
+$63.5M
Cap. Flow
% of AUM
5.91%
Top 10 Holdings %
Top 10 Hldgs %
36.46%
Holding
509
New
13
Increased
172
Reduced
270
Closed
23
Top Buys
| 1 |
Apple
AAPL
|
$12.2M |
| 2 |
Amazon
AMZN
|
$8.41M |
| 3 |
Microsoft
MSFT
|
$6.53M |
| 4 |
Analog Devices
ADI
|
$4.63M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$3.68M |
Top Sells
| 1 |
iShares Silver Trust
SLV
|
$7.9M |
| 2 |
ProShares Ultra Gold
UGL
|
$7.89M |
| 3 |
Arista Networks
ANET
|
$6.7M |
| 4 |
Gilead Sciences
GILD
|
$5.26M |
| 5 |
TSMC
TSM
|
$3.61M |
Sector Composition
| 1 | Technology | 36.93% |
| 2 | Healthcare | 24.36% |
| 3 | Consumer Discretionary | 11.82% |
| 4 | Communication Services | 11.17% |
| 5 | Consumer Staples | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Zymeworks
ZYME
$1.14B
| $165K | 0.02% |
13,816
-789
| -5% | -$9.4K |
|
327
Xeris Biopharma Holdings
XERS
$1.26B
| $164K | 0.02% |
29,903
-1,708
| -5% | -$9.38K |
|
328
Zoetis
ZTS
$67.6B
| $162K | 0.02% |
986
| – | – |
|
329
Day One Biopharmaceuticals
DAWN
$775M
| $161K | 0.02% |
20,330
-1,053
| -5% | -$8.35K |
|
330
Mineralys Therapeutics
MLYS
$2.32B
| $159K | 0.01% |
9,996
-557
| -5% | -$8.85K |
|
331
Praxis Precision Medicines
PRAX
$987M
| $153K | 0.01% |
4,044
+92
| +2% | +$3.48K |
|
332
Evolus
EOLS
$495M
| $153K | 0.01% |
12,701
-725
| -5% | -$8.72K |
|
|
AVDL
333
Avadel Pharmaceuticals
AVDL
$1.52B
| $151K | 0.01% |
19,328
-1,104
| -5% | -$8.64K |
|
334
Replimune Group
REPL
$494M
| $151K | 0.01% |
15,448
-869
| -5% | -$8.47K |
|
335
Xencor
XNCR
$611M
| $150K | 0.01% |
14,133
-706
| -5% | -$7.51K |
|
336
Intellia Therapeutics
NTLA
$1.29B
| $148K | 0.01% |
20,764
-832
| -4% | -$5.92K |
|
337
Anavex Life Sciences
AVXL
$807M
| $146K | 0.01% |
17,062
-918
| -5% | -$7.88K |
|
338
Rocket Pharmaceuticals
RCKT
$354M
| $143K | 0.01% |
21,388
+2,059
| +11% | +$13.7K |
|
|
LENZ
339
LENZ Therapeutics
LENZ
$1.2B
| $142K | 0.01% |
5,516
-315
| -5% | -$8.1K |
|
340
Cogent Biosciences
COGT
$1.82B
| $137K | 0.01% |
22,836
-586
| -3% | -$3.51K |
|
341
Fortrea Holdings
FTRE
$1.06B
| $136K | 0.01% |
17,992
-1,028
| -5% | -$7.76K |
|
342
Prothena Corp
PRTA
$460M
| $134K | 0.01% |
10,797
-612
| -5% | -$7.57K |
|
343
AbCellera Biologics
ABCL
$1.26B
| $133K | 0.01% |
59,771
-2,858
| -5% | -$6.37K |
|
344
Arbutus Biopharma
ABUS
$813M
| $133K | 0.01% |
38,009
-2,170
| -5% | -$7.57K |
|
345
Schrodinger
SDGR
$1.42B
| $127K | 0.01% |
6,410
| – | – |
|
346
ArriVent BioPharma
AVBP
$822M
| $125K | 0.01% |
6,759
-386
| -5% | -$7.14K |
|
347
CureVac
CVAC
$1.21B
| $125K | 0.01% |
44,998
-2,570
| -5% | -$7.12K |
|
348
Hertz
HTZ
$1.7B
| $123K | 0.01% |
31,200
| – | – |
|
349
uniQure
QURE
$982M
| $123K | 0.01% |
11,574
+512
| +5% | +$5.43K |
|
350
Castle Biosciences
CSTL
$684M
| $114K | 0.01% |
5,719
-220
| -4% | -$4.4K |
|